Lactococcus lactis-derived vesicles for eosinophilic inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases, which are characterized by eosinophilic infiltration and excessive mucus production in respiratory organs, with existing probiotics like Bifidobacterium breve-derived vesicles showing limited therapeutic efficacy.
Innovation Solution
Lactococcus lactis-derived vesicles are used as an active ingredient in pharmaceutical, inhalant, food, and quasi-drug compositions to inhibit airway hyperresponsiveness, reduce eosinophilic infiltration, and modulate the immune response from Th2 to Th1, thereby alleviating eosinophilic inflammatory and Th2 hypersensitivity immune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing probiotics like Bifidobacterium breve-derived vesicles are used, then some therapeutic effect is achieved, but the efficacy is limited and insufficient for treating eosinophilic inflammatory diseases
Solution Approach 1:
The patent changes the bacterial source parameter from Bifidobacterium breve to Lactococcus lactis, which produces vesicles with different immunomodulatory properties. The L. lactis-derived vesicles demonstrate superior efficacy in reducing eosinophilic infiltration and mucus production compared to B. breve vesicles, representing a parameter change that resolves the limited efficacy problem
Solution Approach 2:
The patent uses vesicles (copying the essential functional components) of Lactococcus lactis bacteria rather than administering whole live bacteria. This copying approach maintains the therapeutic benefits while improving safety and efficacy, as the vesicles can be produced in large quantities and standardized for consistent therapeutic effect
2Reliability
If probiotics are used to prevent allergic reactions, then regulatory T cells producing IL-10 are induced, but the effect is insufficient for eosinophilic inflammatory diseases requiring Th2 to Th1 immune response shift
Solution Approach 1:
Instead of relying on the conventional probiotic mechanism of inducing IL-10 producing regulatory T cells (Th2 pathway), the patent inverts the approach by using L. lactis-derived vesicles that actively shift the immune response from Th2 to Th1 pathway. This inversion is evidenced by the increased IFN-γ secretion and decreased IL-4, IL-5, and IL-13 levels, directly counteracting the Th2 hypersensitivity that characterizes eosinophilic inflammatory diseases
Data Source
AI summary
Provided is a composition for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases, comprising Lactococcus lactis-derived vesicles, and it was confirmed that, when Lactococcus lactis-derived vesicles according to the presently claimed subject matter were administered to a Th2 hypersensitivity immune disease mouse model, the vesicles inhibited eosinophilic inflammation and the consequent functional and histopathological changes. It was also confirmed that the vesicles inhibited the secretion of Th2 cytokines such as IL-5 and IL-13 in T cells of the Th2 hypersensitivity immune disease mouse model, which is shown by inducing IL-12 secretion that suppresses a Th2 immune response in dendritic cells, which are antigen-presenting cells. Thus, the Lactococcus lactis-derived vesicles according to the presently claimed subject matter are expected to be effectively used in a composition and the like for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases.